Our-Mission
slide00

World Kidney Day 2022

World Kidney Day 2022–Kidney Health for All

In 2022, World Kidney Day was marked on March 10.

 

 

Peer-Review Policy

 The journals of Society of Diabetic Nephropathy Prevention perform an exact peer-review process to verify the strength of the study and confirm the scientific precision of the manuscripts. All papers will assign to the editorial review. Independent peer-reviewers with related knowledge on the submitted papers assess the papers to support editors to define the validity of a manuscript for publication in this journal. Once a manuscript is submitted by the corresponding author, all authors are notified about the submission and the corresponding author can track the manuscript in his account which is made on the Journals’ websites. The Editor-in-Chief of each journal inspects the submitted manuscript.

The editorial workflow gives the Editor-in-Chief the authority to reject any manuscript because of inappropriateness of its subject, lack of quality, or incorrectness of its results.

Only the Editor-in-Chief can approve a manuscript for publication, whereas editors recommend manuscripts for acceptance to the Editor-in-Chief.

Peer Review Type

The journals of Society of Diabetic Nephropathy Prevention  use a double-blind peer review system where the authors do not know who considered their paper.

Peer Review Process

The editorial office conduct an initial assessment on submitted papers to guarantee their accordance with editorial policies, ethical standards and submission guidelines. Therefore, the papers should first be formatted according to the journal’s style.

The submissions are predominantly will be assessed by one of our statisticians who test the papers for the statistical methods. After completion of editorial checks, then the submission is considered by the Editor-in-Chief who determines, the paper directed for peer review through assign to the one of the Associate Editor/ Section Editor/Co-editor, based on the subject of the manuscript, to inspect the paper. The Associate Editor/ Section Editor/Co-editor, leads the peer-review process for papers within their field of working. If they determined that the paper is not of enough value to go toward the standard peer-review process or if the title of the paper is not suitable to the journal scope, the paper will be rejected with no more handling. If the Editor ascertained that the submitted paper is of adequate quality and detected to be within the scope of the journal, then the paper will directed toward one of editorial board members according to the title of the paper, the accessibility of the editors, and the lack of any probable conflicts of interest with the submitting authors for a secondary check of the paper. After assessment, the manuscript will be sent to a minimum of two external reviewers for peer reviewing.  If an Editor, employee, or Editorial Board Member, submits a paper, it is appointed to an independent Editor who will conduct the peer review process, then results of the review process directly assigned to the Editor-in-Chief. 

In our journals, all authors and reviewers will adhere to COPE Core Practices and WAME guidelines to keep all ethics of peer-review, particularly the process of the manuscripts that involves their personal relationship. The Editor-in-Chief will finally receive all peer-review results and will decide to accept or reject the papers. The Editor-in-Chief or any other Editor who is responsible for the initial and final decision  of the papers should release themselves to peer-review or take decisions on the papers that is bring out by authors who affiliated to the same institute/university as of the editor, or if they are a family member or a collaborator. They can therefore suggest somebody else on the editorial board who could offer a neutral opinion on the manuscript.

Peer Reviewers

Authors can also recommend reviewers, who should have a current publication record in the field of the paper and should not be from the same department as the author.

Appeals and Complaints

Any appeal on the assessed papers or any complaint during the peer-review period should be submitted by writing to the Editor-in-Chief. All cases will be conducted according to the COPE guidelines.

When the reviewers submitted their reports, the editor can make one of the following editorial recommendations:

  1. Acceptance: the manuscript could be e-Published. We try to reduce this process to maximum two weeks. Before e-Publication, corresponding author can verify a proof copy of the paper. After e-Publication, paper will be in a queue to be published in the journal.
  2. Minor revision: authors will receive comments upon their manuscript, in which the authors will be asked to submit a revised copy beside cover letter showing authors’ rejoinders, and a marked copy utilizing Track Changes in Review menu of Microsoft Word Documents. Revised manuscript should be submitted in one month after decision letter. Otherwise, authors need to go through a resubmission process.
  3. Major revision: it means a chance to reorganize the manuscript to meet the required scientific criteria for another review process. Authors should pay more attention to reviewers’ comments and focus on their highlighted points. Editor may/may not request the authors to resubmit their revised manuscript beside cover letter and a marked copy. Revised manuscript should be submitted in one month after decision letter. Otherwise, authors need to go through a resubmission process.
  4. Reject: in most cases, methodological and scientific concerns are the main origins of rejection. Causes of rejection will be sent to the authors to provide more chance for them for publication in other journals.
  5. Withdraw: if the manuscript does not meet the scopes of the Journal, it will be withdrawn with suggestion to be sent to another journal.

If the decision is, “review again after minor changes or review again after major changes, the system will automatically notify the corresponding author about the reviewer’s suggestions and recommendations.

The author/authors will have a period of time to submit the revised form of the article. After this, the Editor-in-Chief will decide if a new stage of review is necessary, and if it is the case, he will select two reviewers.

After the new review stage, according to the reviewer’s recommendations, the Editor-in-Chief will take the final decision.

 

Author Guidelines

Society of Diabetic Nephropathy Prevention (publisher) follows the guidelines of COPE (COPE Code of Conduct and Best Practice Guidelines; https://publicationethics.org/files/Code_of_conduct_for_journal_editors_Mar11.pdf and https://publicationethics.org/core-practices) and respects the ICMJE (the International Committee of Medical Journal Editors Recommendations; https://www.icmje.org/recommendations) for Editing, Reporting, Conduct and Publication of scientific papers in the health and therapeutic journals and the updated Good Publication Practice guideline regarding authorship (https://www.ismpp.org/gpp3). Submission of a paper to this journals means that all authors have read and agreed to all materials and content. The papers must follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals from the International Committee of Medical Journal Editors (ICMJE).

Online submission
Authors should only submit their papers directly via the online system of each journal. The editorial office do not consider the submissions by intermediate companies or mediators. Manuscripts should be submitted by corresponding author or one of the authors, however it should not be submitted by anyone out of the manuscript. The corresponding author is responsible to submit the copyright alongside with the paper submission. Only English written papers are accepted. The articles also should be edited by a native speaker to guarantee that, the paper was compiled by a standard English grammar. We strongly suggest the authors to conduct a professional English check before paper submission to prevent hinders with the review process. The submission also should be provided by a cover letter, which should include a statement declaring that the study complies with current ethical considerations.

 

Article Types


Research (Original) Article
Research (Original) papers is a central study, which should describe noteworthy and original findings (up to ~8000 words, including tables, figures and references). The publication of these papers is according to the novelty, scientific reliability with regard to the analysis methods.
To prepare the Original papers, the authors are required to respect the EQUATOR Network for original studies.
Research articles must have an approval from their Institutional /Hospital/University Ethics Committee for all investigations involving human or animal subjects.

Data Availability Statement

The journal’s data sharing policy brightly incites the authors to create all datasets, makes the relied conclusion of the article to be available for the readers, editors and reviewers without unnecessary limitation.
Authors are demanded to create a Data Availability Statement in their article addressed that data is available near the corresponding author for presentation and where they can be found. In conditions, which the research data are not publicly available or there is legal or ethical issues, the condition should be clearly mentioned in the Data Availability Statement alongside with any circumstances for accessing the data. However, the judgement to publish will not be affected by whether or not; the authors share their research data.

Review Articles
A Review study (up to ~8000 words, including tables, figures and references) is considered as a summary of several articles, to cover a recent topic by authorities in its field. Review papers should comprise a serious discussion on the current studies and present a reasonable conclusion concerning previous investigations and debates.

Systematic Reviews
Systematic Review papers are literature studies dedicated on a demand which verifies all high-quality published studies related to that demand. Systematic Review papers must be prepared as the following format; Introduction and Methods, then Results and Discussion. The topic should be well described. The objective of a Systematic Review study must lead to an evidence-based conclusion. The Methods section should contain a clear method of literature search strategy. Accordingly, data extraction procedure and grading of evidence, finally kind of performed analysis should be described well. Meanwhile, authors are requested to conform to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines(www.prisma-statement.org).


MOOSE: Meta-analyses of observational studies in epidemiology must be reported according to MOOSE guideline (http://www.ijo.in/documents/14MOOSE_SS.pdf)
EQUATOR: To find the reporting guidelines see (www.equator-network.org).
Authors are requested to register their Systematic Reviews in the Prospero (international prospective register of systematic reviews) by the following link; https://www.crd.york.ac.uk/prospero/

Case Report
Case presentation is a case study, referred to the explanation a patient’s history, which addresses a considerable new perception to a patient with an unusual and distinguished history. Submissions could be a single case or as a case series. The uniqueness of the case may show by the presentation, the investigation, the phenotype, and case management.
To follow with the CARE guidelines (http://www.care-statement.org/) is strongly recommended. The authors should follow the CARE checklist (http://www.care-statement.org/resources/checklist) that should be submitted as a distinct file.

Commentary
Commentaries papers, which published along with the article, address the important points of the article and many expanding them. Additionally, the commentaries underline/discuss the positive points of the article with some comments. Commentaries are the author’s opinion are not original materials. Commentary papers are requested by the Editors as an invitation during peer-review and are related to the field of expertise of the peer-reviewers.

Photoclinic
In this section, an interesting photo in the field of nephrology supported by a brief description and a few references (up to five).

Epidemiology and prevention
This part is devoted mostly to epidemiology and prevention of treatment in the area of nephrology.

News and views
News and views are devoted mostly to recent findings of treatment in nephrology and renal transplantation, accompanied by the views of the authors.

Hypothesis
This type of paper is related to an opinion or a hypothesis on a subject in the area of treatment in nephrology, kidney transplantation and hemodialysis. Hypothesis articles are short manuscripts that present an original hypothesis. The article should set out a clearly identified hypothesis and be supported by adequate references.

Editorial
Editorials articles addressed a specific or a recent subject, relevant to the scope of the journal. Editorials are written by an editor or other members.

Letter-to-Editor
Letters are papers to expand the other published articles in the journal. These papers addressed the author’s opinion on an original/review or case report. Letters could debate a recently published paper and may explore the finding of the articles and discuss the controversies along with author’s opinion who wrote the letter.
The editor office then will share such letters to the authors of the primary article prior to publication to receive the author’s reply to the letter, for the next issue of the journal.

Copyright
The copyright of the article should be completed and signed by the authors, along with submission. The copyright will send by the corresponding author through email if each journal.
The authors approve that, the Society of Diabetic Nephropathy Prevention as the publisher have an exclusive unlimited license to publish the article under a Creative Commons license and confirm that, this publisher is the original publisher. During submission of a paper, the authors consent to its publication under the applicable Creative Commons license and to the terms and conditions of the Publisher’s Licensing Agreement. The Society of Diabetic Nephropathy Prevention recommends submitting of original photos and materials whenever possible. All authors should sign the copyright individually. Besides, the corresponding author are responsible for copyright infringement. The authors will provide their name, affiliation with their emails accordingly.

Declaration of Conflicting Interests
The Declaration of Conflicting Interests strategy denotes our official policy, which refers to a conflict of interest (COI) statement by the author.
The Society of Diabetic Nephropathy Prevention follows the guidelines of Committee on Publication Ethics (COPE) [ https://publicationethics.org/competinginterests ] declares in its Guidelines on Good Publication Practice [https://www.ismpp.org/gpp3], and the ICMJE recommendations for guidance concerning conflicts of interest.
Some instances of COI can comprise the subsequent items;

-Received money for consulting.

-Received money for research

-Relationship with the company

-Received money for attending in a interrelated symposia, or congress

However, if there are any other, interests the readers might sense that the results of the study may affected the original paper; the authors accordingly should state them.


Accordingly, at the time of paper submission, the authors would declare all information on financial source or other conflicts, which could affect the decisions on manuscript. Therefore, the authors should complete and sign the ICMJE Form for Disclosure of Potential Conflicts of Interest, while the manuscripts submission will not be conducted without completing this form.

Authors’ Contribution Statement
In the Authors’ Contributions section, a short statement explaining the role of each author. Contributors to the article which do not conform to the ICMJE Criteria for Authorship should be accredited in the Acknowledgement part of the paper.
If a contributor is deleted from or included to the authors’ list after submission, a separate letter to explain along with a new signed copyright form is necessary.

Author contributions should be clarified based on the following items;
Conceptualization;
Methodology;
Validation;
Formal Analysis;
Investigation;
Resources;
Data Curation;
Writing—Original Draft Preparation;
Writing—Review and Editing;
Visualization;
Supervision;
Project Administration;
Funding Acquisition;

Availability of materials
The Methods section of an original paper should contain enough data to permit a reader to understand the investigation. This Journal advices authors to employ; https://www.protocols.io like an open access repository for their detailed methodology. For protocols recorded in https://www.protocols.io, please cite this record in your methods part and comprise its DOI in the references. Society of Diabetic Nephropathy Prevention as the publisher encourages the adding the Research Resource Identifiers in the methods and materials section (https://www.rrids.org/). See also; https://scicrunch.org/resources

Article Preparation

Formatting
The manuscripts should be prepared as the Word file. Page number numbering should be provided too. Footnotes are not allowed.
All abbreviations should be expanded when they used for the first time in the abstract part and in the body of the manuscript both.
For drugs, the generic names of medications should be employed. Regarding registered trade drugs, they should be marked with the superscript registration symbol ® or ™ whenever, they used.

Manuscript Preparing
Manuscripts submitted for research and review articles in the respective journal should be divided into the following sections

Title
Title page
Structured Abstract
Keywords
Text Organization
Conclusion
Limitations of the study
Acknowledgement
Authors’ contribution
Ethical considerations
Conflicts of interest
Data Availability Statement
Consent for Publication
Funding/Supports
References
Figures/Illustrations (if any)
Tables (if any)
Supplementary Materials (if any)

Title Page
The paper must contain a title and a running title no more the eighty characters. Under the title, a list of authors’ names along with their affiliations which includes, first the department, then university/ organization, city and state/province, and finally the country.

The authors should also provide their ORCID (Open Researcher and Contributor Identifier) by the following link; https://orcid.org

The corresponding authors should provide their mobile/ telephone number and e-mail address (mostly academic and general emails both).

All the original research articles, systematic reviews and meta-analyses must be accompanied with a structured abstract. Ideally, each abstract should include the following sub-headings, but these may vary according to requirements of the article.
Introduction
Objectives
Patients/Materials and Methods
Results
Conclusion

Keywords
At least three words related to the manuscript should be selected.

Introduction
This section should clearly and briefly, (up to 600 words) provide an adequate background with relevant references, avoiding a detailed literature survey or a summary of the results. The last paragraph should address the main objectives of the work.

Objectives
This section serves as a brief description about the aim of the study

Patients and Methods (Materials and Methods for preclinical investigations)
This section should provide sufficient details to allow the work to be reproduced, with details of supplier (i.e., company’s name, city, country) and catalogue number when appropriate. Methods already published, should be indicated by a reference: only relevant modifications should be described. The company’s name, city and country of manufacturer of the major equipment should be given. Unexpected hazards encountered during the experimental work should be noted. Any unusual hazards inherent in the use of chemicals, procedures or equipments in the investigation should be clearly identified. In cases where a study involves the use of live animals or human subjects, the author should include a statement that all experiments were performed in compliance with the relevant laws and institutional guidelines, and also state the institutional committee(s) that has approved the experiments. They should also include a statement that informed consent was obtained for any experimentation with human subjects.

Results
Results should be clear, descriptive and concise. Attention should be paid to the matter of significant figures and tables. The same data should not be presented in more than one figure or in both a figure and a table.
Basically, as a rule, interpretation of the results should be reserved for the discussion section of a full original research article.

Discussion
The discussion should explore the significance of the results of the work (without repeating them) in comparison with others similar reports. Extensive citations and discussion of published literature should be avoided.

Conclusion
The main question of the work should be very concisely stated and the final conclusions of the study may be presented in a short “Conclusions” section, which may stand alone or form a subsection of a Discussion or Results and Discussion section(s).

Text
Submit your text in DOC format. Do not embed figures or tables in this document. These should be submitted as separate files.

Tables
Tables should be created with a word processor and saved in either DOC or RTF format. Do not embed tables in your text. Tables should be on separate pages and saved as one file in DOC format.

Figures
To ensure the highest print quality, the figures must be submitted in either TIF or EPS format according to the following minimum resolutions:

• 1200 dpi (dots per inch) for black and white line art (simple bar graphs, charts, etc.)
• 300 dpi for halftones (black and white photographs)
• 600 dpi for combination halftones (photographs that also contain line art such as labeling or thin lines), figures should be saved as individual files. Vector-based figures (e.g. figures created in Adobe Illustrator) should be submitted in EPS format.

Color figures must be submitted in a CMYK color.

Ethical considerations


General cautions

Every experimental or clinical study may raise controversial ethical issues (e.g., Institutional Ethical Approval for working with animal or human subjects). Thus, Journal of Nephropharmacology expects all authors, reviewers and editors to consider COPE, ICMJE and Equator Network’s reporting guidelines in medical ethics plus scientific writing.
Ethical issues (including plagiarism, misconduct, data fabrication, falsification, double publication or redundancy) must completely considered by the authors.
Authors reporting experimental studies on human subjects must include a statement of assurance at the end of the manuscript which address; (1) informed consent was obtained from each patient enrolled in the study and (2) the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee. In studies involving animal experimentation, provide assurance that all animals received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985) and the general care of the experimental animals used for this study was conducted in compliance with the Animal Welfare Act (http://www.nap.edu/openbook.php?record_id=5140&page=114).

Statement of ethics in original articles
The original articles published must follow the internationally accepted institutes/universities for original works and their reporting. Papers will be rejected if the journal’s office found that the study has not been provided by a proper ethical review board, and when troubles developed after publication can result to the retraction, correction, or explanation of the mooted concern conform to COPE guidelines.

Therefore, human subject studies must be conducted upon the approval of the ethics committee along with appropriate participants’ informed consent according to the tenets of Helsinki Declaration.

In the manuscript, the authors must address the name of the ethics committee who approved the research protocol along with the reference number.

For all investigations communicating human body, written informed consent to participate in the research should be received from participants or their parents/legal guardians. Besides, a statement detailing this statement should addressed in the paper.

According to the ICMJE recommendations regarding the protection of research participants, authors should avoid spread of identifying information of participants unless strictly necessary for the submission . In this condition, the authors should certify that the study patients have offered the written consent for presentation of that information in a publication.

Likewise, the research concerning embryonic germ cells, human embryonic stem cells, cell lines or induced pluripotent stem cells must conform with the 'Guidelines for the Conduct of Human Embryonic Stem Cell Research' (ISSCR).

In line with the ICMJE recommendations for Clinical Trials, they should be recorded in a country which have an accessible registry recognized by the ICMJE or WHO, thereby a clinical trial number must be definitively mentioned in the paper.
Registration in the following trial registers is acceptable. Additionally, any registry that is a fundamentally register of the WHO International Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/network/primary/en/index.html).

https://www.thaiclinicaltrials.org (Thai Clinical Trials Registry)
http://www.irct.ir
http://www.clinicaltrials.gov
http://www.trialregister.nl
http://www.umin.ac.jp

Articles reporting clinical trials should follow the guidelines their research protocol, like the CONSORT flow chart for randomized controlled trials(www.consort-statement.org) . Moreover, authors must use TREND for the non-randomized trial researches, or other clear guidelines as mentioned in the Equator network website.

Society of Diabetic Nephropathy Prevention (as the publisher of this journal), adhere to the WHO definition of clinical trials.

Please also visit guidelines at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html
STARD and TRIPOD: Investigations of diagnostic accuracy should be reported according to STARD guidelines; (www.stard-statement.org) and TRIPOD guidelines; (www.tripod-statement.org).

STROBE: Observational studies (cohort, case-control, or cross-sectional designs) should be reported consistent with the STROBE statement, and must be submitted with their protocols; (www.strobe-statement.org).

The clinical trials must contain registration number mentioned in the manuscripts following the end of abstract part and the end of the manuscripts both.

Experimental investigations on animals must follow the authors' Institutional Animal Care and Use Committee (IACUC) or an equal ethical committee (local) and should respect the internationally documented rules like the ARRIVE recommendations. Hence, in the paper, the authors must address the name of the local/university ethical committee along with the reference approved number of the study protocol.

COREQ: Qualitative research should be described according to the COREQ recommendations; (see; https://academic.oup.com/intqhc/article/19/6/349/1791966).

CHEERS: Economic evaluations must be reported according to CHEERS guidelines; (www.bmj.com/content/346/bmj.f1049).

STREGA: Genetic association studies must be reported according to STREGA recommendations; (www.medicine.uottawa.ca).

The authors are encouraged to submit the ethical committee reference letter alongside with the paper submission.

Statement of ethics in Systematic Review papers
The registered systematic reviews must contain a number mentioned in the manuscripts at the end of abstracts and at the end of the manuscripts both.
Systematic Review papers, authors are also encourage to obtain an institutional ethical approval from their university/hospital.

Statement of ethics in case reports
The manuscript should contain a sentence delegating that, a written informed consent for publication was taken and from whom
Accordingly, case reports/ case series should have an approval from their Institutional /Hospital/University Ethics Committee for all investigations involving human or animal subjects.
If the patient was deceased, publication consent statement should be taken from their first relatives.
Consent for publication for babies/children should be taken from the parents or legal guardians.
The consent statement must be available to the journal if demanded.
The authors are encouraged to submit the ethical committee reference letter alongside with the paper submission.

Informed Consent
In the case of research on human subjects, informed consent and other ethical considerations should be mentioned in the "methods" section of the manuscript. The author should include a statement that informed consent was obtained for any experimentation with human subjects. As we follow the ICMJE, please consider their guideline for more information. In cases where a study involves the use of live animals or human subjects, the author should also include a statement that all experiments were performed in compliance with the relevant laws and institutional guidelines, and also state the institutional committee(s) that has approved the experiments. Moreover, the templates can be seen from WHO.

The authors can use the below form to obtain consent for publication from the participant

Consent form


I …………………………….………………………………..…………....

[Name] give my consent for information about myself/my child or ward/my relative (circle as appropriate) to be published in
………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………….…………
[The journal name, manuscript number and corresponding author].
I understand that the information will be published without my/my child or ward’s/my relative’s (circle as appropriate) name attached, but that full anonymity cannot be guaranteed.
I understand that the text and any pictures or videos published in the article will be freely available on the internet and may be seen by the general public. The pictures, videos and text may also appear on other websites or in print, may be translated into other languages or used for commercial purposes.
I have been offered the opportunity to read the manuscript.
Signing this consent form does not remove my rights to privacy.

Name…………………………………

Date………………………………….

Signed………………………………..

Author name………………………..

Date…………………………………

Signed………………………………

Please keep this consent form in the patient’s case files. The manuscript reporting this patient’s details should state that ‘Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient/parent/guardian/ relative of the patient. A copy of the consent form is available for review by the Editor of this journal.


Conflicts of Interest
The authors must declare any conflict of interests of contributed authors very briefly in a separate paragraph at the end of the paper. All sources of funding should be declared; unless otherwise the following sentence should be given “Authors declare no conflict of interests”.
To prevent the information on potential conflict of interest for authors from being overlooked or misplaced, mention this information in the cover letter. Authors must identify any potential financial conflicts of interest before the review process begins. Declared conflict of interest will not automatically result in rejection of paper but the editors reserve the right to publish any declared conflict of interest alongside accepted. The following would generally be regarded as potential conflicts of interest:
1. Direct financial payment to an author for the research or manuscript production by the sponsor of a product or service evaluated in an article.
2. Ownership of shares by an author in the company sponsoring a product service evaluated in an article (or in a company sponsoring a competing product).
3. Personal consultant for companies or other organizations with a financial interest in the promotion of particular health care products and services.

Source of Funding
Authors are required to specify the source of funding for their research when submitting a paper alongside with grant/award number for example, “This study was financially supported by xxxx (Grant number#....). Suppliers of materials also should be mentioned by their location too.
Likewise, if a study did not have any specific funding source, or is part of the employment of the authors, therefore the name of the employer will be necessary. Authors will have to definitively mention that the funder was in charge of writing, editing, or decision to publish the paper.

Acknowledgements
Authors should acknowledge any scientific, technical, statistical and financial supports. Contributors other than coauthors may be very briefly acknowledged in a separate paragraph at the end of the paper. All sources of funding should be declared.

Implication for health policy makers/practice/research/medical education
This part will be used for better understanding the main message of the article in a simple way. Maximum word count should not be more than 50-120.

References
Authors are responsible for the accuracy of all references. These should be numbered in order of their appearance in the text and listed in a separate section following the text, double-spaced.

Numbered references should appear at the end of the paper and should consist of surnames and initials of all authors when six or less (when seven or more list the first six then et al). Title of article, name of journal abbreviated according to Index Medicus style, year, volume, and first and last page numbers along with doi number of the articles.

Examples
-Haaskjold YL, Bjørneklett R, Bostad L, Bostad LS, Lura NG, Knoop T. Utilizing the MEST score for prognostic staging in IgA nephropathy. BMC Nephrol. 2022 Jan 11; 23:26. doi: 10.1186/s12882-021-02653-y.

-Paranhos RM, De Souza Figueiredo GA, De Abreu GR, Ferreira GC, Fonseca GG, Simões E Silva AC. Immunoglobulin A nephropathy in paediatrics: An up-to-date. Nephrology (Carlton). 2022;27:307-317. doi: 10.1111/nep.13987.

For books, names and initials of all authors, the full title, place of publication, publisher, year of publication, and page number should be given.

The references should be numbered sequentially in the order in which they are first cited in the text. Other materials with a DOI, like preprints or datasets may be included too.

Copyediting and Proofs
Manuscripts accepted for publication by Society of Diabetic Nephropathy Prevention as the publisher will undergo a proofreading to check for grammar mistakes and spelling. Our publisher’s style is based on The Chicago Manual of Style(https://www.chicagomanualofstyle.org/home.html).

Then an e-mail containing the PDF proofs will be sent to the corresponding author, which must check the proofs and answer to all questions that have been provided as the comments of the proof within 48 hours.
Authors are not allowed to change the text of the proof and should answer the comments or provide new comments to correct the text.

DOI Number
All papers will get a DOI number as a unique identifier on each article. DOIs are valuable for recognizing and citing online articles

Errata and Retractions
Society of Diabetic Nephropathy Prevention as the publisher is committed to maintaining the accuracy and integrity of the scientific record. Retractions will be mentioned where necessitated according to the COPE guidelines. Errors in an article that influence the material of the paper, like results, figures or the manuscript’s metadata, like the author’s list, will be modified by the publication of an Erratum. Authors can send an email to report errors in their manuscripts, by addressing, article title with DOI number the place of error.

 

Editorial Policy

Open Access
The Society of Diabetic Nephropathy Prevention follows the Budapest Open Access Initiative (BOAI) funding model by the following link; https://www.budapestopenaccessinitiative.org/ (2019).
All content our journals is freely available to readers/ authors and all institutions without a limitation period. Individuals can search, copy, print, read and download and also distribute full texts of the papers.
In our journals, the accepted articles by peer review will be published under a Creative Commons Attribution License (CC-BY) https://creativecommons.org/licenses/by/4.0/ (2019). Besides, in our journals no charge is needed for submitting the manuscripts.

Permissions
It is the duty of the authors to get the permission from copyright containers for copying photos, figures or tables will not be published. The authors should submit the certification of permission along with the submission.

Disclaimer
Facts and opinions in papers published in the three journals of Society of Diabetic Nephropathy Prevention are exclusively the personal statements of respective authors. Authors are responsible for all contents in their article(s) including accuracy of the facts, statements and citing the resources.

Advertising Policy
Journals of Society of Diabetic Nephropathy Prevention do not publish any advertisement. Our journal also have not any direct marketing actions, counting the requesting of papers.

The policy of Society of Diabetic Nephropathy Prevention on preprint articles
Authors are not allowed to submit preprint papers.

Publication Ethics and Malpractice Statement


Publication and authorship

1. All submitted manuscripts to our journals are subject to strict peer-review process by at least two reviewers that are experts in the area Nephrology/Pharmacology.
2. The factors that are taken into account in review are relevance, soundness, significance, originality, readability and language.
3. The possible decisions include acceptance, acceptance with revisions, or rejection.
4. If authors are encouraged to revise and resubmit a submission, there is no guarantee that the revised submission will be accepted.
5. Rejected manuscripts will not be re-reviewed.
6. The manuscript acceptance is constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism.
7. No research can be included in more than one publication.

Authors' responsibilities

1. Authors must certify that their manuscripts are their original work.
2. Authors must certify that the manuscript has not previously been published elsewhere.
3. Authors must certify that the manuscript is not currently being considered for publication elsewhere.
4. Authors must participate in the peer review process.
5. Authors are obliged to provide retractions or corrections of mistakes.
6. All Authors mentioned in the paper must have significantly contributed to the research.
7. Authors must state that all data in the paper are real and authentic.
8. Authors must notify the editors of any conflicts of interest.
9. Authors must identify all sources used in the creation of their manuscript.
10. Authors must report any errors they discover in their published paper to the editors.

Please complete authors’ agreement form provided on the journal website and send through email to the journal.

Reviewers' responsibilities

1. Reviewers should keep all information regarding papers confidential and treat them as privileged information.
2. Reviews should be conducted objectively, with no personal criticism of the author
3. Reviewers should express their views clearly with supporting arguments
4. Reviewers should identify relevant published work that has not been cited by the authors.
5. Reviewers should also call to the editor- in-chief's attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.
6. Reviewers should not review manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

For more information, please look at the checklist for review provided on the journal website.

Editors' responsibilities

1. Editors have complete responsibility and authority to reject/accept an article.
2. Editors are responsible for the contents and overall quality of the publication.
3. Editors should always consider the needs of the authors and the readers when attempting to improve the publication.
4. Editors should guarantee the quality of the papers and the integrity of the academic record.
5. Editors should publish errata pages or make corrections when needed.
6. Editors should have a clear picture of a research's funding sources.
7. Editors should base their decisions solely one the papers' importance, originality, clarity and relevance to publication's scope.
8. Editors should not reverse their decisions nor overturn the ones of previous editors without serious reason.
9. Editors should preserve the anonymity of reviewers.
10. Editors should ensure that all research material they publish conforms to internationally accept ethical guidelines.
11. Editors should only accept a paper when reasonably certain.
12. Editors should act if they suspect misconduct, whether a paper is published or unpublished and make all reasonable attempts to persist in obtaining a resolution to the problem.
13. Editors should not reject papers based on suspicions; they should have proof of misconduct.
14. Editors should not allow any conflicts of interest between staff, authors, reviewers and board members.

Plagiarism
Society of Diabetic Nephropathy Prevention is committed to publish only original materials (materials that neither has been published elsewhere, nor is under review elsewhere). Journal of Nephropharmacology is powered by the iThenticate® software, a plagiarism detector software that detects the originality of content submitted before publication. If plagiarism is recognized, we act based on flowcharts and workflows regulated by the COPE.

Plagiarism could be the following items

o Direct copying the text from other articles
o Copying concepts, photos, or data from other published sources
o Copying the text from the own previous published materials

Plagiarism Policies
If plagiarism is recognized, the manuscript will be rejected. Additionally, if plagiarism is detected after publication of the paper, the will retract according to the COPE guidelines.

Duplicate Submission
Papers, which have been published elsewhere, or to be under review elsewhere, will incur duplicate submission/publication sanctions. If authors have used their own previously published study, or study that is currently under review, as the basis for a submitted manuscript, they are required to cite the previous paper and indicate how their submitted manuscript offers novel contributions beyond those of the previous work.

Citation Manipulation
Submitted papers that are found to include citations whose primary purpose is to increase the number of citations to a given author’s article, or to articles published in a particular journal, will incur citation manipulation sanctions.

Data Fabrication and Falsification
Submitted papers that are found to have either fabricated or falsified experimental results, including the manipulation of images, will incur data fabrication and falsification sanctions.

Improper Author Contribution or Attribution
All listed authors must have made a significant scientific contribution to the study in the paper and approved all its claims. It is important to list everyone who made a significant scientific contribution, including students and laboratory technicians.

Redundant Publications
Redundant publications involve the inappropriate division of study outcomes into several articles.

Process for Identification of and Dealing with Allegations of Research Misconduct
Society of Diabetic Nephropathy Prevention (SDNP) (http://www.sdiabeticnephropathy.com) as the publisher will take practical steps, which comprise technological and personal knowledge available to identify and block the publication of papers where research misconduct has arisen, containing citation manipulation, plagiarism, and data falsification/fabrication among others. The Society of Diabetic Nephropathy Prevention respects the COPE's guidelines (http://publicationethics.org/resources/guidelines) in dealing with allegations.

 

The footprint of androgen sensitive serine protease (TMPRSS2) in gender mortality with COVID-19

Male gender is an obvious risk factor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mortality rate is higher in men than women. Undoubtedly, gender-related behavioral factors, such as higher amounts of smoking, alcohol consumption, and biological differences in immune systems could make males more vulnerable. The role of androgen-responsive elements (AREs) of transmembrane serine proteases type II (TMPRSS2) gene as one of the major players of male dominancy in severe COVID-19 infection has been under appreciated and needs to be clarified.

COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment

The novel coronavirus disease 2019 (COVID-19) is a rapidly expanding infection around the world. The world Health Organization (WHO) in March 2020 announced the Coronavirus pandemic. This infection causes many deaths on daily basis. Therapeutic options are currently limited. It is revealed that COVID-19 binds to human angiotensin-converting enzyme 2 (ACE2) to enter the host cells. One of the activities of ACE2 is hydrolyzing the active bradykinin metabolite [des-Arg973] BK (DABK). A decreased activity or reducing expression of ACE2 by the virus impairs the inactivation of DABK. This enhances its signaling through the bradykinin B1 receptor (BKB1R) and could lead to fluid extravasation and leukocyte recruitment to the lung. Targeting the bradykinin system by either blocking the bradykinin production or blocking bradykinin receptors may open a new potential therapeutic window for the treatment of COVID-19 induced acute respiratory distress syndrome (ARDS) particularly before patients enter the irreversible stages. 

Keywords: COVID-19, SARS-CoV, Bradykinin, Lung injury, ACE2, Coronavirus, Acute respiratory distress syndrome, Angiotensin converting enzyme2 

Coronavirus-nephropathy; renal involvement in COVID-19

Implication for health policy/practice/research/medical education: 

Renal disturbances by coronavirus disease 2019 (COVID-19), consisted of acute kidney injury, due to acute tubular necrosis induced by sepsis, hydration, cytokine storm syndrome, rhabdomyolysis and hypoxia. As the direct cytopathic effect of virus on various renal cells has been detected in previous studies, direct virus invasion to the renal tubular cells and interstitium or glomeruli is possible. Previous studies showed that coronavirus enters into the cells by angiotensin-converting enzyme II receptors that are extensively presented in the renal cells. Further, acute kidney injury in COVID-19 is strongly associated with higher mortality and morbidity and is an indicator for survival with Coronavirus infection. In the overall approach to patients with COVID-19 infection, special attention should be paid to control of classical risk factors of kidney injury. 

Please cite this paper as: Valizadeh R, Baradaran A, Mirzazadeh A, Bhaskar LVKS. Coronavirus-nephropathy; renal involvement in COVID-19. J Renal Inj Prev. 2020; 9(2): e18. doi: 10.34172/jrip.2020.18. 

SARS-CoV-2 and Fabry nephropathy: potential risks and the pathophysiological perspective

Fabry disease is an X-linked disorder due to mutations in alpha-galactosidase A gene. It affects the kidney in virtually all patients with classical and some late onset variants. Podocytes, endothelial cells, vascular smooth muscle, tubular and mesangial cells are involved in different ways. Proteinuria and chronic kidney disease are the result of the progressive accumulation of the enzyme substrates globotriaosylceramide (GB3) and lyso-GB3 in the cytoplasm of these cells (mainly in lysosomes), which leads to cellular and organ dysfunction and eventually renal failure and end-stage kidney disease. Specific enzyme replacement therapy and pharmacological chaperone are at present the main therapeutic approach. After enzyme infusion, the delivered enzyme is differentially uptaken by kidney cells in three different ways: By Mannose-6-phosphate receptor, megalin and sortilin. The delivered enzyme gradually clears cells from the accumulation of the glycosphingolipids and contributes to a cellular healthier status. The recent pandemic caused by SARS-CoV-2 has led to the collapse of health systems around the world and to thousands of deaths. Kidney involvement has been reported to range from proteinuria to acute kidney injury, 30% of which may require renal replacement therapy. In this review the potential causes for which Fabry patients should be at increased risk and the necessity not to discontinue therapy are discussed.

Infectious pathways of SARS-CoV-2 in renal tissue

Implication for health policy/practice/research/medical education: 

Coronavirus disease in 2019 (COVID-19) has spread around the world and caused significantly pandemic mobility and mortality. Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) usually infects lungs first and involves other organs including kidneys subsequently. Acute kidney injury and proteinuria in patients with COVID19 are resulted from the direct infection of the spikycrowned viruses to proximal tubules and podocytes, leading to acute tubular injury and collapsing focal segmental glomerulosclerosis. Therefore treatment strategy should target against the direct infection of SARS-CoV2 to the renal tissue.

Please cite this paper as: Yin W, Zhang PL. Infectious pathways of SARS-CoV-2 in renal tissue. J Nephropathol. 2020;9(4):e37. DOI: 10.34172/jnp.2020.37.

Collapsing glomerulopathy following COVID-19 infection; possible relationship with APOL1 kidney risk alleles in African-Americans

Collapsing glomerulopathy (CG) is being increasingly reported in African American patients with COVID-19 infection during the current pandemic. It is possible that CG following COVID-19 infection in this population may be linked to underlying APOL1 kidney risk alleles, which are not uncommon in this ethnic group. This lesion should be considered in the differential diagnosis of rapidly declining renal function in association with heavy proteinuria in the setting of COVID-19 disease, especially in patients of African ancestry.

 

Perspectives on the relationship of renal disease and coronavirus disease 2019

Coronavirus disease 2019 (COVID-19) is now a pandemic and its death toll is rocketing up. Patients with acute kidney injury (AKI) and chronic kidney disease (CKD) are at high risk of developing COVID-19 complications and COVID-19 infection can also lead to renal dysfunction. Considering the importance of kidney function in COVID-19 patients, the present review is aimed to dig into the available evidence about kidney and COVID-19. We summarize the mechanisms underlying the renal injury in COVID-19 patients, and treatment strategies in dialysis and kidney transplant patients. We conclude, it is imperative to highlight the early monitoring of patients with AKI and carefully control kidney function during severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection.

 

Implication for health policy/practice/research/medical education:

It is imperative to highlight the early monitoring of patients with AKI and carefully control kidney function during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Please cite this paper as: Yalameha B, Roshan B, Bhaskar LVKS, Mohmoodnia L. Perspectives on the relationship of renal disease and coronavirus disease 2019. J Nephropharmacol. 2020;9(2):e22. DOI: 10.34172/npj.2020.22

 

 

Systematic Review & Meta-Analysis

Prof. Sayed Mohsen Hosseini, Ph.D. in Biostatistics, Department of Biostatistics & Epidemiology, School of Public Health, Isfahan University of Medical Sciences,
Isfahan, Iran

Management team

CO-EDITORS
Parviz Khajehdehi, Professor of Nephrology, Shiraz University of Medical Sciences, Shiraz, Iran
Mehri Kadkhodaee, Professor of Renal Physiology, Tehran Medical Sciences University, Tehran, Iran

ASSOCIATE EDITOR
Muhamad Mubarak (Asia), Professor of Pathology, Histopathology Department, S.I.U.T., Karachi, Pakistan
Mohammadreza Ardalan, Professor of Nephrology, Tabriz University of Medical Sciences, Tabriz, Iran
Heshmatollah  Shahbazian, Professor of Nephrology, Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran
Behzad Einollahi, Professor of Nephrology, Baqiyatallah University of Medical Sciences, Tehran, Iran

EDITORS
Farahnak Assadi, Emeritus Professor of Pediatrics, Chief Section of Nephrology, Rush University Medical Center Chicago, Illinois, USA
Ali Nayer, Associate Professor of Medicine, Division of Nephrology and Hypertension, University of Miami, USA
Lionel Rostaing, Professor and Consultant in Clinical Transplantation Toulouse University Hospital Toulouse, France

CONSULTANT
Farhad Shokraneh, Trials Search Coordinator (TSC), Cochrane Schizophrenia Group.  The Institute of Mental Health, The University of Nottingham, Nottingham, UK


TECHNICAL EDITOR
Hafez Hassanzadeh, Tabriz University of Medical Sciences, Tabriz, Iran
Milad Baradaran-Ghahfarokhi, Medical Physics and Medical Engineering Department, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail address: This email address is being protected from spambots. You need JavaScript enabled to view it.

Publication Ethics and Malpractice Statement

Publication Ethics and Malpractice Statement in the Journals of Society of Diabetic Nephropathy Prevention

Publication and authorship

1.    All submitted manuscripts to the Journals of Society of Diabetic Nephropathy Prevention are subject to strict peer-review process by at least two international reviewers and one local reviewer that are experts in the area nephrology and nephropathology.
2.    The factors that are taken into account in review are relevance, soundness, significance, originality, readability and language.
3.    The possible decisions include acceptance, acceptance with revisions, or rejection.
4.    If authors are encouraged to revise and resubmit a submission, there is no guarantee that the revised submission will be accepted.
5.    Rejected manuscripts will not be re-reviewed.
6.    The manuscript acceptance is constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism.
7.    No research can be included in more than one publication

Authors' responsibilities
1.    Authors must certify that their manuscripts are their original work.
2.    Authors must certify that the manuscript has not previously been published elsewhere.
3.    Authors must certify that the manuscript is not currently being considered for publication elsewhere.
4.    Authors must participate in the peer review process.
5.    Authors are obliged to provide retractions or corrections of mistakes.
6.    All Authors mentioned in the paper must have significantly contributed to the research.
7.    Authors must state that all data in the paper are real and authentic.
8.    Authors must notify the editors of any conflicts of interest.
9.    Authors must identify all sources used in the creation of their manuscript.
10.    Authors must report any errors they discover in their published paper to the editors.

Please complete authors’ agreement form provided on the journal website and send    through email to the journal

Reviewers' responsibilities
1.    Reviewers should keep all information regarding papers confidential and treat them as privileged information.
2.    Reviews should be conducted objectively, with no personal criticism of the author
3.    Reviewers should express their views clearly with supporting arguments
4.    Reviewers should identify relevant published work that has not been cited by the authors.
5.    Reviewers should also call to the editor- in-chief's attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.
6.    Reviewers should not review manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

For more information please look at the checklist for review provided on the journal website.
 
Editors' responsibilities
1.    Editors have complete responsibility and authority to reject/accept an article.
2.    Editors are responsible for the contents and overall quality of the publication.
3.    Editors should always consider the needs of the authors and the readers when attempting to improve the publication.
4.    Editors should guarantee the quality of the papers and the integrity of the academic record.
5.    Editors should publish errata pages or make corrections when needed.
6.    Editors should have a clear picture of a research's funding sources.
7.    Editors should base their decisions solely one the papers' importance, originality, clarity and relevance to publication's scope.
8.    Editors should not reverse their decisions nor overturn the ones of previous editors without serious reason.
9.    Editors should preserve the anonymity of reviewers.
10.    Editors should ensure that all research material they publish conforms to internationally accept ethical guidelines.
11.    Editors should only accept a paper when reasonably certain.
12.    Editors should act if they suspect misconduct, whether a paper is published or unpublished, and make all reasonable attempts to persist in obtaining a resolution to the problem.
13.    Editors should not reject papers based on suspicions, they should have proof of misconduct.
14.    Editors should not allow any conflicts of interest between staff, authors, reviewers and board members.

Informed Consent

All persons have individual rights that are not to be infringed. Individual participants in investigations have, the right to decide what happens to the personal data gathered, to what they have said during an investigation or an interview, and also to any photograph that was taken.
Therefore it is important that all participants gave their informed consent in writing prior to inclusion in the investigation. Identifying details (names, dates of birth, identity numbers and other information) of the participants that were studied should not be published in written descriptions, photographs, and genetic profiles unless the information is essential for scientific purposes and the participant (or parent or guardian if the participant is incapable) gave written informed consent for publication.
 
You can use the below form to obtain consent for publication from the participant.

Consent form
 
I …………………………….………………….... [Name] give my consent for information about myself/my child or ward/my relative (circle as appropriate) to be published in …………………………………………………………………………

[The journal of parathyroid disease, manuscript number and corresponding author].
 
I understand that the information will be published without my/my child or ward’s/my relative’s (circle as appropriate) name attached, but that full anonymity cannot be guaranteed.
I understand that the text and any pictures or videos published in the article will be freely available on the internet and may be seen by the general public. The pictures, videos and text may also appear on other websites or in print, may be translated into other languages or used for commercial purposes.
I have been offered the opportunity to read the manuscript.
 
Signing this consent form does not remove my rights to privacy.
 
Name…………………………………

Date………………………………….

Signed………………………………..

Author name………………………..

Date…………………………………

Signed………………………………
 
Please keep this consent form in the patient’s case files. The manuscript reporting this patient’s details should state that ‘Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient/parent/guardian/ relative of the patient. A copy of the consent form is available for review by the editor of this journal.

Journal of Preventive Epidemiology
Journal of Nephropharmacology
Journal of Nephropathology

 

 

Journals of society of diabetic nephropathy prevention follow the principles and issues of, the Committee on Publication Ethics (COPE).

 

 

Journals of Society of Diabetic Nephropathy Prevention , are licensed under a Creative Commons Attribution 4.0 License.

 

 

 

 

 

 

 

 

 

 

Site Traffic

Today26
This month26
Total108612

Saturday, 01 October 2022 17:04



 

 

 

Healthy eating and diabetes

 

 

 

 

 



 

 

Current Date & Time

Saturday, 01 October 2022